Pre-made Avdoralimab benchmark antibody ( Whole mAb, anti-C5AR1 therapeutic antibody, Anti-C5AR/C5R1/CD88 Antibody) for drug discovery and mechanism of action (MOA) researchCat No.: GMP-Bios-ab-039
Pre-Made Avdoralimab biosimilar, Whole mAb, Anti-C5AR1 Antibody: Anti-C5AR/C5R1/CD88 therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Avdoralimab (IPH 5401, formerly NN 8210) is a complement C5a receptor antagonist (Anti-C5aR-215) recombinant human monoclonal antibody, being developed by Innate Pharma, for the treatment of solid tumours, chronic spontaneous urticaria [chronic urticaria in development table], Bullous-pemphigoid and COVID-19 pneumonia.
* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry
|Catalog No.||Package||Price(In USD)||Qty (Quantity)||Sum(In USD)|
|Products Name (INN Index)||Pre-Made Avdoralimab biosimilar, Whole mAb, Anti-C5AR1 Antibody: Anti-C5AR/C5R1/CD88 therapeutic antibody|
|Highest_Clin_Trial (Jan '20)||Phase-II|
|100% SI Structure||None|
|99% SI Structure||None|
|95-98% SI Structure||None|
|Companies||Novo Nordisk;Innate Pharma|
|Conditions Active||Bullous pemphigoid;COVID-19;Urticaria;Liver cancer;Non-small cell lung cancer;Solid tumours|
|Conditions Discontinued||Rheumatoid arthritis|